Marcel Rozencweig - Concepedia

Author

Marcel Rozencweig

Institut Jules Bordet

Also Known As

M Rozencweig, M. ROZENCWEIG, M. Rozencweig, MARCEL ROZENCWEIG, Marcel Rozencweig, Rozencweig M., Rozencweig, M

206

Publications

5.1K

Citations

H-Index

117

Concepts

All Affiliations

Institut Jules Bordet Bristol-Myers Squibb (United States)European Organisation for Research and Treatment of Cancer Université Libre de Bruxelles Ospedale San Giovanni Bellinzona

About

Marcel Rozencweig is an author at Institut Jules Bordet specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	50	2.1K
2	Health Sciences	4	4	114
3	Engineering	3	3	251
4	Arts	1	1	173
5	Language Studies	1	1	173

Marcel Rozencweig

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Daunomycin-induced cardiotoxicity in children and adults Daniel D. Von Hoff, Marcel Rozencweig, Maxwell W. Layard, The American Journal of Medicine Cardiovascular DiseasePediatric Heart DiseaseDaunomycin-induced CardiotoxicityPediatricsCardiovascular Pharmacology	1977	434
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial Cora N. Sternberg, Daniel P. Petrylak, Oliver Sartor, Journal of Clinical Oncology	2009	339
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Von Hoff, Richard L. Schilsky, Reichert Cm, PubMed Drug SafetyMedicinal ChemistryMedicineToxic EffectsLiver Function Tests	1980	338
The cardiotoxicity of anticancer agents. Von Hoff, Marcel Rozencweig, Martine Piccart PubMed	1982	202
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery Franco M. Muggia, Andrea Bonetti, James D. Hoeschele, Journal of Clinical Oncology Translation StudiesLiterary TheoryFranco MMolecular BiologyItalian Studies	2015	173
Methodology for the assessment of new dichotomous diagnostic tests Maurice J. Staquet, Marcel Rozencweig, Young Jack Lee, Journal of Chronic Diseases ReliabilityEngineeringDifferential DiagnosisDiagnostic CriterionDiagnosis	1981	156
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer José Baselga, Alexey Manikhas, Javier Cortés, Annals of Oncology Breast OncologyNonpegylated Liposomal DoxorubicinMedicinePharmacologyPhase Iii Trial	2014	94
Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. M. Staquet, David P. Byar, S B Green, PubMed Chemoprevention StrategySolid Organ TransplantationTransplantation MedicineImmunologyP388 Prescreen	1983	77
Overview of Taxol safety. N Onetto, Renzo Canetta, Benjamin Winograd, PubMed Drug SafetyTherapeutic Drug MonitoringPeripheral NeuropathyChemical SafetyPhase Ii Program	1993	73
Overview of Phase I Trials of 2′,3′-Dideoxyinosine (ddI) Conducted on Adult Patients Marcel Rozencweig, C. McLaren, Mohan Beltangady, Clinical Infectious Diseases	1990	66

Page 1